Appointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development

REDWOOD CITY, Calif. and WUHAN, China, Dec. 16, 2020 (GLOBE NEWSWIRE) -- XWPharma Ltd. today announced that Michael M. Morrissey, Ph.D. has been appointed to the company’s Board of Directors. Dr. Morrissey brings extensive experience as a scientist, leader of highly productive Research and Development organizations, and chief executive officer of a fully-integrated, widely respected biopharma company.

“We are very excited to welcome Mike to our Board,” said Leonard Blum, XWPharma President and CEO. “As a seasoned R&D and company leader, his perspective will be invaluable as we prioritize the multiple high potential opportunities our research unit has identified and navigate the evolving landscape of creating first of their kind therapeutics for patients suffering from CNS disorders with compelling unmet needs.